• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Bio-Techne Corp

    5/30/25 4:30:27 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TECH alert in real time by email
    SD 1 tech-20250530xsd.htm SD

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549


    FORM SD


    SPECIALIZED DISCLOSURE REPORT


    BIO-TECHNE CORPORATION

    (Exact name of registrant as specified in its charter)


    ​

    Minnesota

    000-17272

    41-1427402

    (State or other jurisdiction of
    incorporation or organization)

    (Commission
    File Number)

    (I.R.S. Employer
    Identification No.)

    ​

    614 McKinley Place NE Minneapolis, MN

    55413

    (Address of principal executive offices)

    (Zip Code)

    ​

    Shane V. Bohnen (612) 851-4841

    (Name and telephone number, including area code, of the person to contact in connection with this report)


    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

    ​

    ☒

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

    ​

    ​

    ​

    1


    ​

    SECTION 1 – CONFLICT MINERALS DISCLOSURE

    Item 1.01 Conflict Minerals Disclosure and Report

    Most of the products Bio-Techne manufactures or contracts to manufacture do not contain conflict minerals. However, under our ProteinSimple brand included in our Analytical Solutions Division, we sell instruments, some of which include tin, tungsten, tantalum and/or gold (“3TG”). We also sell two other small groups of reagent products, one under our Novus Biologicals and R&D Systems brands that contains 3TG. These product lines collectively are the subject of this Report.

    ​

    Conflict Minerals Disclosure

    A copy of Bio-Techne Corporation’s Conflict Minerals Report is provided as Exhibit 1.01 hereto and is publicly available at www.bio-techne.com .

    Item 1.02 Exhibit

    As specified in Section 2, Item 2.01 of this Form SD, the Company is hereby filing its Conflict Minerals Report as Exhibit 1.01 to this Form SD.

    SECTION 2 – EXHIBITS

    Item 2.01 Exhibits

    Exhibit 1.01 – Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

    ​

    2


    ​

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Date: May 30, 2025

    By:

    /s/ Shane V. Bohnen

    ​

    Name:

    Shane V. Bohnen

    ​

    Title:

    Senior Vice President, General Counsel and Secretary

    ​

    3


    Get the next $TECH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TECH

    DatePrice TargetRatingAnalyst
    7/22/2025$65.00Overweight
    Stephens
    7/9/2025$65.00Buy
    TD Cowen
    5/30/2025$59.00Overweight
    Wells Fargo
    4/9/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    3/18/2025$75.00Outperform
    Evercore ISI
    2/19/2025$88.00 → $68.00Outperform → Neutral
    Robert W. Baird
    5/22/2024$85.00Buy → Neutral
    Citigroup
    2/8/2024$80.00Sector Outperform
    Scotiabank
    More analyst ratings

    $TECH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Kelderman Kim exercised 36,132 shares at a strike of $44.33 and covered exercise/tax liability with 32,933 shares, increasing direct ownership by 8% to 42,203 units (SEC Form 4)

      4 - BIO-TECHNE Corp (0000842023) (Issuer)

      7/17/25 5:04:37 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Herr Amy E. exercised 1,280 shares at a strike of $44.33 and sold $63,705 worth of shares (1,280 units at $49.77) (SEC Form 4)

      4 - BIO-TECHNE Corp (0000842023) (Issuer)

      6/11/25 4:20:06 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Higgins John L exercised 12,000 shares at a strike of $21.84, increasing direct ownership by 25% to 60,196 units (SEC Form 4)

      4 - BIO-TECHNE Corp (0000842023) (Issuer)

      5/5/25 4:18:21 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results

      MINNEAPOLIS, July 17, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, August 6, 2025, at 8:00 a.m. CDT to review its fourth quarter and fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: August 6, 2025 Dial-in: 1-800-274-8461 or 1-203-518-9814 (for international callers) Conference ID: TECHQ4 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referen

      7/17/25 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Spear Bio Announces Strategic Partnership with Bio-Techne to Accelerate the Deployment of Its Next-Generation Immunoassay Technology

      Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, is pleased to announce a strategic distribution partnership with Bio-Techne Corporation (NASDAQ:TECH), a global leading provider of innovative reagents, instruments, and solutions for life-science research and clinical diagnostics. The partnership significantly expands global access to Spear Bio's groundbreaking SPEAR UltraDetect™ immunoassays, focusing initially on the neurology research market. The introductory SPEAR UltraDetect offering targets biomarkers pivotal to neurodegenerative diseases, such as phosphorylated tau 231 (pTau 231), phosphorylated tau 217 (pTau 217), glial fibrillary acidi

      7/15/25 9:03:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bio-Techne and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultrasensitive Biomarker Detection

      MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology. Under the agreement, Bio-Techne will distribute Spear Bio's ultrasensitive immunoassays for challenging low-abundance biomarkers, including key Alzheimer's disease biomarkers such as phosphorylated tau 217 (pTau 217), GFAP, neurofilament light (Nf-L), and phosphorylated tau 231 (pTau 231). The initial offering will focus on key biomarkers supporting translational research in Alzheimer's disease. This partnership follows Bio-Techne's partici

      7/15/25 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stephens resumed coverage on Bio-Techne with a new price target

      Stephens resumed coverage of Bio-Techne with a rating of Overweight and set a new price target of $65.00

      7/22/25 7:51:31 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TD Cowen initiated coverage on Bio-Techne with a new price target

      TD Cowen initiated coverage of Bio-Techne with a rating of Buy and set a new price target of $65.00

      7/9/25 8:26:14 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wells Fargo initiated coverage on Bio-Techne with a new price target

      Wells Fargo initiated coverage of Bio-Techne with a rating of Overweight and set a new price target of $59.00

      5/30/25 8:40:12 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    SEC Filings

    See more
    • SEC Form 144 filed by Bio-Techne Corp

      144 - BIO-TECHNE Corp (0000842023) (Subject)

      6/9/25 4:19:36 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SD filed by Bio-Techne Corp

      SD - BIO-TECHNE Corp (0000842023) (Filer)

      5/30/25 4:30:27 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Bio-Techne Corp

      SCHEDULE 13G/A - BIO-TECHNE Corp (0000842023) (Subject)

      5/14/25 10:45:26 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Financials

    Live finance-specific insights

    See more
    • Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results

      MINNEAPOLIS, July 17, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, August 6, 2025, at 8:00 a.m. CDT to review its fourth quarter and fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: August 6, 2025 Dial-in: 1-800-274-8461 or 1-203-518-9814 (for international callers) Conference ID: TECHQ4 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referen

      7/17/25 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS

      MINNEAPOLIS, May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ending March 31, 2025. Third Quarter FY2025 Highlights Third quarter organic revenue increased by 6% (4% reported) to $316.2 million.GAAP earnings per share (EPS) was $0.14 versus $0.31 one year ago. Delivered adjusted EPS of $0.56 compared to $0.48 one year ago.Improved pharma end market conditions, combined with strong commercial execution in Protein Sciences led to 7% organic growth (6% reported) in the segment.Delivered adjusted operating margin of 34.9% (12.2% reported) compared to 33.0% (22.1% reported) in the prior year driven by profitability initia

      5/7/25 6:30:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM

      MINNEAPOLIS, May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2025. The quarterly dividend will be payable May 30, 2025, to all common shareholders of record on May 19, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne also announced this week that its board of directors has approved a new share repurchase program authorizing the repurchase of up to $500 million of common stock. The new share repurchase program begins May 8, 2025 and replaces the previous program. The timing and number of shares to be r

      5/7/25 6:30:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Leadership Updates

    Live Leadership Updates

    See more
    • Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors

      MINNEAPOLIS, Feb. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President of the Chan Zuckerberg Biohub Network, a group of nonprofit research institutes established to create tools required to understand the mysteries of the cell to ultimately cure, prevent, and manage human disease. Since joining th

      2/4/25 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS

      MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various s

      4/30/24 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT

      MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has over two decades of experience as a senior life sciences leader, most recently serving as Executive Vice President and Chief Operating Officer for Azenta, where he was responsible for Life Sciences Products, Services, and all commercial operations of the business. Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne's Molecular D

      1/5/24 7:00:00 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bio-Techne Corp

      SC 13G - BIO-TECHNE Corp (0000842023) (Subject)

      11/14/24 1:22:36 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Bio-Techne Corp (Amendment)

      SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)

      2/13/24 5:00:46 PM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Bio-Techne Corp (Amendment)

      SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)

      2/9/23 11:12:40 AM ET
      $TECH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care